<PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">39433732</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>24</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2044-5385</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>21</Day></PubDate></JournalIssue><Title>Blood cancer journal</Title><ISOAbbreviation>Blood Cancer J</ISOAbbreviation></Journal><ArticleTitle>Impact of COVID-19 on outcomes with teclistamab in patients with relapsed/refractory multiple myeloma in the phase 1/2 MajesTEC-1 study.</ArticleTitle><Pagination><StartPage>186</StartPage><MedlinePgn>186</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">186</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41408-024-01160-1</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>van de Donk</LastName><ForeName>Niels W C J</ForeName><Initials>NWCJ</Initials><Identifier Source="ORCID">0000-0002-7445-2603</Identifier><AffiliationInfo><Affiliation>Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands. n.vandedonk@amsterdamumc.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bahlis</LastName><ForeName>Nizar</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0001-7353-7034</Identifier><AffiliationInfo><Affiliation>Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Costa</LastName><ForeName>Luciano J</ForeName><Initials>LJ</Initials><Identifier Source="ORCID">0000-0001-5362-2469</Identifier><AffiliationInfo><Affiliation>University of Alabama at Birmingham, Birmingham, AL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mateos</LastName><ForeName>María-Victoria</ForeName><Initials>MV</Initials><Identifier Source="ORCID">0000-0003-2390-1218</Identifier><AffiliationInfo><Affiliation>University Hospital of Salamanca/IBSAL/CIC/CIBERONC, Salamanca, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nooka</LastName><ForeName>Ajay K</ForeName><Initials>AK</Initials><Identifier Source="ORCID">0000-0003-4165-6869</Identifier><AffiliationInfo><Affiliation>Winship Cancer Institute, Emory University, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perrot</LastName><ForeName>Aurore</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-0131-8689</Identifier><AffiliationInfo><Affiliation>Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garfall</LastName><ForeName>Alfred L</ForeName><Initials>AL</Initials><Identifier Source="ORCID">0000-0003-2791-5748</Identifier><AffiliationInfo><Affiliation>Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thaman</LastName><ForeName>Pragya</ForeName><Initials>P</Initials><Identifier Source="ORCID">0009-0005-4505-6344</Identifier><AffiliationInfo><Affiliation>Janssen Research &amp; Development, Bridgewater, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qi</LastName><ForeName>Keqin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development, Titusville, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uhlar</LastName><ForeName>Clarissa</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development, Spring House, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chastain</LastName><ForeName>Katherine</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development, Raritan, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Doyle</LastName><ForeName>Margaret</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Janssen Sciences Ireland, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Usmani</LastName><ForeName>Saad Z</ForeName><Initials>SZ</Initials><Identifier Source="ORCID">0000-0002-5484-8731</Identifier><AffiliationInfo><Affiliation>Memorial Sloan Kettering Cancer Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>n/a</GrantID><Agency>Janssen Research and Development (Janssen R&amp;D)</Agency><Country /></Grant><Grant><GrantID>n/a</GrantID><Agency>Janssen Research and Development (Janssen R&amp;D)</Agency><Country /></Grant><Grant><GrantID>n/a</GrantID><Agency>Janssen Research and Development (Janssen R&amp;D)</Agency><Country /></Grant><Grant><GrantID>n/a</GrantID><Agency>Janssen Research and Development (Janssen R&amp;D)</Agency><Country /></Grant><Grant><GrantID>n/a</GrantID><Agency>Janssen Research and Development (Janssen R&amp;D)</Agency><Country /></Grant><Grant><GrantID>n/a</GrantID><Agency>Janssen Research and Development (Janssen R&amp;D)</Agency><Country /></Grant><Grant><GrantID>n/a</GrantID><Agency>Janssen Research and Development (Janssen R&amp;D)</Agency><Country /></Grant><Grant><GrantID>n/a</GrantID><Agency>Janssen Research and Development (Janssen R&amp;D)</Agency><Country /></Grant><Grant><GrantID>n/a</GrantID><Agency>Janssen Research and Development (Janssen R&amp;D)</Agency><Country /></Grant><Grant><GrantID>n/a</GrantID><Agency>Janssen Research and Development (Janssen R&amp;D)</Agency><Country /></Grant><Grant><GrantID>n/a</GrantID><Agency>Janssen Research and Development (Janssen R&amp;D)</Agency><Country /></Grant><Grant><GrantID>n/a</GrantID><Agency>Janssen Research and Development (Janssen R&amp;D)</Agency><Country /></Grant><Grant><GrantID>n/a</GrantID><Agency>Janssen Research and Development (Janssen R&amp;D)</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Blood Cancer J</MedlineTA><NlmUniqueID>101568469</NlmUniqueID><ISSNLinking>2044-5385</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CoiStatement>NWCJvdD has served in a consulting/advisory role for AbbVie, Adaptive Biotechnologies, Amgen, Bayer, BMS, Celgene, Janssen, Kite Pharma, Merck, Novartis, Pfizer, Roche, Servier, and Takeda; and has received research funding from Amgen, BMS, Celgene, Cellectis, Janssen, and Novartis. NB has served in a consulting/advisory role for Amgen, Celgene, Janssen, Karyopharm Therapeutics, Pfizer, Sanofi, and Takeda; received honoraria from AbbVie, Amgen, Celgene, Genentech/Roche, GSK, Janssen, Karyopharm Therapeutics, Sanofi, and Takeda; and has received research funding from Celgene, Janssen, and Pfizer. LJC has served in a consulting role for AbbVie, Amgen, BMS, Pfizer, and Sanofi; has received grants or contracts from AbbVie, Amgen, and BMS; and has received research funding from Janssen. M-VM reports honoraria from and membership on a board of directors and/or advisory committee for Amgen, BMS/Celgene, GSK, Janssen-Cilag, Pfizer, Sanofi, and Takeda; is a speakers bureau member for Janssen-Cilag; and is a board of directors and/or advisory committee member for Oncopeptides. AKN has served on advisory boards and received honoraria from Adaptive Biotechnologies, Amgen, BeyondSpring, BMS, Cellectar Biosciences, GSK, Janssen, Karyopharm Therapeutics, Oncopeptides, ONK Therapeutics, Pfizer, Sanofi, Secura Bio, and Takeda; received grant/research support (to university) from Aduro Biotech, Amgen, Arch Oncology, BMS, Cellectar Biosciences, Cellectis, Genentech, GSK, Janssen, Karyopharm Therapeutics, Kite Pharma, Merck, Pfizer, and Takeda; and received grant/research support for investigator-initiated studies from Amgen, GSK, Janssen, Merck, and Takeda. AP has received honoraria or consultancy from AbbVie, Amgen, BMS, Janssen, Pfizer, Sanofi, and Takeda. ALG has served in a consulting or advisory role for Abbvie, Amgen, Bristol Myers Squibb/Celgene, CDR-Life, GlaxoSmithKline, Gracell, Janssen Oncology, Novartis, Regeneron, and Smart Immune; received travel, accommodations, or expenses from Janssen; has a patent in the field of CAR-T cell therapy; and received research funding from Crispr Therapeutics, Janssen Oncology, Novartis, and Tmunity Therapeutics, Inc. PT, KQ, CU, KC, and MD are employees of Janssen. SZU has served in a consulting/advisory role for AbbVie, Amgen, BMS/Celgene, Celgene, Genentech, Genentech/Roche, Gilead Sciences, GSK, Janssen Oncology, K36 Therapeutics, Karyopharm Therapeutics, and Takeda; and has received research funding from AbbVie, Amgen, Array BioPharma, BMS, Celgene, Gilead, GSK, Janssen Oncology, Merck, Pharmacyclics, Sanofi, Seagen, and SkylineDx.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>22</Day><Hour>0</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>22</Day><Hour>0</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>21</Day><Hour>23</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39433732</ArticleId><ArticleId IdType="pmc">PMC11494165</ArticleId><ArticleId IdType="doi">10.1038/s41408-024-01160-1</ArticleId><ArticleId IdType="pii">10.1038/s41408-024-01160-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Raje N, Anaissie E, Kumar S, Lonial S, Martin T, Gertz M, et al. Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group. Lancet Haematol. 2022;9:e143–161.</Citation><ArticleIdList><ArticleId IdType="pubmed">35114152</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubinstein S, Derman B. Infection rates are high across the multiple myeloma continuum, not just with bispecific antibodies. Eur J Cancer. 2023;189:112926.</Citation><ArticleIdList><ArticleId IdType="pubmed">37307686</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez-Lopez J, Hernandez-Ibarburu G, Alonso R, Sanchez-Pina J, Zamanillo I, Lopez-Munoz N, et al. Impact of COVID-19 in patients with multiple myeloma based on a global data network. Blood Cancer J. 2021;11:198.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8661359</ArticleId><ArticleId IdType="pubmed">34893583</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Kuraishy H, Al-Gareeb A, Mohammed A, Alexiou A, Papadakis M, El-Saber Bathia G. The potential link between Covid-19 and multiple myeloma: a new saga. Immun Inflamm Dis. 2022;10:e701.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9673426</ArticleId><ArticleId IdType="pubmed">36444620</ArticleId></ArticleIdList></Reference><Reference><Citation>Chari A, Samur K, Martinez-Lopez J, Cook G, Biran N, Yong K, et al. Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set. Blood. 2020;136:3033–40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7759145</ArticleId><ArticleId IdType="pubmed">33367546</ArticleId></ArticleIdList></Reference><Reference><Citation>Curigliano G, Banejee S, Cervantes A, Garassino M, Garriso P, Girard N, et al. Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus. Ann Oncol. 2020;31:1320–35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7836806</ArticleId><ArticleId IdType="pubmed">32745693</ArticleId></ArticleIdList></Reference><Reference><Citation>Hungria V, Garnica M, de Queiroz Crusoé E, de Magalhaes Filho R, Martinez G, Bittencourt R, et al. Managing patients with multiple myeloma during the COVID-19 pandemic: recommendations from an expert panel – ABHH Monoclonal Gammopathies Committee. Hematol Transfus Cell Ther. 2020;42:200–5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7218372</ArticleId><ArticleId IdType="pubmed">32405620</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathieu E, Ritchie H, Rodés-Guirao L, Appel C, Giattino C, Hasell J, et al. Coronavirus pandemic (COVID-19). 2020. https://ourworldindata.org/coronavirus.</Citation></Reference><Reference><Citation>Nooka AK, Rodriguez C, Mateos M-V, Manier S, Chastain K, Banerjee A, et al. Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC-1 study. Cancer. 2024;130:886–900.</Citation><ArticleIdList><ArticleId IdType="pubmed">37960969</ArticleId></ArticleIdList></Reference><Reference><Citation>Tregoning J, Flight K, Higham S, Wang Z, Pierce B. Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape. Nat Rev Immunol. 2021;21:626–36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8351583</ArticleId><ArticleId IdType="pubmed">34373623</ArticleId></ArticleIdList></Reference><Reference><Citation>US Food and Drug Administration. Coronavirus (COVID-19) update: FDA authorizes first oral antiviral for treatment of COVID-19. 2021. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-oral-antiviral-treatment-covid-19.</Citation></Reference><Reference><Citation>Moreau P, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriel A, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022;387:495–505.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10587778</ArticleId><ArticleId IdType="pubmed">35661166</ArticleId></ArticleIdList></Reference><Reference><Citation>Cortes-Selva D, Casneuf T, Vishwamitra D, Stein S, Perova T, Skerget S, et al. Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma: correlative analyses from MajesTEC‑1. Blood. 2022;140:241–3.</Citation></Reference><Reference><Citation>Mohan M, Chakraborty R, Bal S, Nellore A, Baljevic M, D’Souza A, et al. Recommendations on prevention of infections during chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma. Br J Haematol. 2023;203:736–46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10700672</ArticleId><ArticleId IdType="pubmed">37287117</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludwig H, Sonneveld P, Facon T, San-Miguel J, Avet-Loiseau H, Mohty M, et al. COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network. Lancet Haematol. 2021;8:e934–e946.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8553271</ArticleId><ArticleId IdType="pubmed">34756169</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreau P, Mateos M-V, Gonzalez Garcia ME, Einsele H, De Stefano V, Karlin L, et al. Comparative effectiveness of teclistamab versus real-world physician’s choice of therapy in LocoMMotion and MoMMent in triple-class exposed relapsed/refractory multiple myeloma. Adv Ther. 2024;41:696–715.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10838813</ArticleId><ArticleId IdType="pubmed">38110653</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>